References
- Silvestri E, Emmi G, Prisco D. Vascular Behçet's disease: new insights in the management of thrombosis. Expert Rev Cardiovasc Ther 2013;11(12):1583-5
- Balta I, Balta S, Koryurek OM, et al. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet's disease without significant cardiovascular involvement. J Eur Acad Dermatol Venereol 2013. [Epub ahead of print]
- Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet's disease. J Am Acad Dermatol 2014;70(2):291-6
- Balta I, Akbay G, Kalkan G, Eksioglu M. Demographic and clinical features of 521 Turkish patients with Behçet's disease. Int J Dermatol 2013. [Epub ahead of print]
- Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet's disease. Yonsei Med J 2007;48(4):573-85
- Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41(1):61-70
- Smith CH, Anstey A V, Barker JNWN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153(3):486-97
- Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (AT TACH) trial. Circulation 2003;107(25):3133-40